(Q41525870)

2 October 2017

1 reference

title

Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications (English)

1 reference

2 October 2017

Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications (English)

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

13 September 2024

1 reference

1 reference

A. Carlsson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9217267

13 September 2024

L. O. Hansson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9217267

13 September 2024

N. Waters

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9217267

13 September 2024

M. L. Carlsson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9217267

13 September 2024

language of work or name

English

0 references

publication date

1 January 1997

1 reference

full work available at URL

2 October 2017

number of pages

20

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0024320597002282?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

https://api.elsevier.com/content/article/PII:S0024320597002282?httpAccept=text/plain

13 September 2024

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

13 September 2024

1 reference

2 October 2017

volume

61

1 reference

2 October 2017

issue

2

1 reference

2 October 2017

page(s)

75-94

1 reference

Receptor activity and turnover of dopamine and noradrenaline after neuroleptics

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Further studies on the accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain. Effect of some phenothiazine analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Antipsychotic drug doses and neuroleptic/dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The current status of the dopamine hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Effect of a striatal spreading depression on the pharmacogenic catatonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Striatal inhomogeneities and basal ganglia function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The muscarine antagonist methscopolamine and the NMDA antagonist AP-5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in opposite directions depending on the dopaminergic tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The role of 5-HT2A receptors in antipsychotic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Muscimol: GABA agonist therapy in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

On the Quantitative Structure-Activity Relationships of Meta-Substituted (S)-Phenylpiperidines, a Class of Preferential Dopamine D2 Autoreceptor Ligands: Modeling of Dopamine Synthesis and Release in Vivo by Means of Partial Least Squares Regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

inferred from DOI database lookup

7 January 2021

based on heuristic

"Perestroika" in the basal forebrain: opening the border between neurology and psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900228-2

inferred from DOI database lookup

7 January 2021

based on heuristic

SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia

47

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

Treatment of schizophrenia: New antidopaminergic strategies

13 September 2024

56

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

European Journal of Pharmacology

13 September 2024

65

author name string

Martin

publication date

1997

1 reference

https://api.crossref.org/works/10.1016/S0024-3205(97)00228-2

13 September 2024

Identifiers

1 reference

2 October 2017

1 reference